These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Alpha-blockers and lower urinary tract function: more than smooth muscle relaxation? Michel MC; Schafers RF; Goepel M BJU Int; 2000 Oct; 86 Suppl 2():23-8; discussion 28-30. PubMed ID: 11501614 [No Abstract] [Full Text] [Related]
8. Alpha adrenoceptor antagonists in the year 2000: is there anything new? Chapple CR Curr Opin Urol; 2001 Jan; 11(1):9-16. PubMed ID: 11148741 [TBL] [Abstract][Full Text] [Related]
9. Increased bladder apoptosis with alpha-1 adrenoceptor antagonists in benign prostatic hyperplasia. Erdoğru T; Gülkesen KH; Kukul E; Yalçinkaya M; Karpuzoğlu G; Baykara M Scand J Urol Nephrol; 2002; 36(3):188-93. PubMed ID: 12201933 [TBL] [Abstract][Full Text] [Related]
10. Silodosin (Rapaflo) for benign prostatic hyperplasia. Med Lett Drugs Ther; 2009 Jan; 51(1303):3-4. PubMed ID: 19122568 [TBL] [Abstract][Full Text] [Related]
11. [Benign prostate hyperplasia: success and limitations of pharmacological therapy]. Madersbacher S; Marszalek M Internist (Berl); 2007 Oct; 48(10):1157-64. PubMed ID: 17426942 [TBL] [Abstract][Full Text] [Related]
12. alpha1-Adrenoceptor subtype selectivity and lower urinary tract symptoms. Schwinn DA; Price DT; Narayan P Mayo Clin Proc; 2004 Nov; 79(11):1423-34. PubMed ID: 15544022 [TBL] [Abstract][Full Text] [Related]
13. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Lowe FC Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685 [TBL] [Abstract][Full Text] [Related]
14. Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Barendrecht MM; Abrams P; Schumacher H; de la Rosette JJ; Michel MC Neurourol Urodyn; 2008; 27(3):226-30. PubMed ID: 17638312 [TBL] [Abstract][Full Text] [Related]
15. The evolving picture of lower urinary tract symptom management. Tubaro A; De Nunzio C; Puccini F; Presicce F Eur Urol; 2015 Feb; 67(2):271-2. PubMed ID: 25457016 [No Abstract] [Full Text] [Related]
16. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P; Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148 [TBL] [Abstract][Full Text] [Related]
18. Mechanisms of action for α Hattori T; Sugaya K Life Sci; 2017 Dec; 191():90-96. PubMed ID: 29032116 [TBL] [Abstract][Full Text] [Related]
19. Drug treatments for lower urinary tract symptoms secondary to bladder outflow obstruction: focus on quality of life. MacDonald D; McNicholas TA Drugs; 2003; 63(18):1947-62. PubMed ID: 12930164 [TBL] [Abstract][Full Text] [Related]
20. [Urodynamic study of lower urinary tract. VI. Clinical application of alpha adrenergic blocker for the treatment of benign prostatic hypertrophy and bladder neck contracture (author's transl)]. Kondo A; Narita H; Otani T; Kobayashi M; Takita T Nihon Hinyokika Gakkai Zasshi; 1978 Oct; 69(10):1232-40. PubMed ID: 83419 [No Abstract] [Full Text] [Related] [Next] [New Search]